Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) Debt to Equity: 2020-2023

Historic Debt to Equity for C4 Therapeutics (CCCC) over the last 2 years, with Jun 2023 value amounting to $0.04.

  • C4 Therapeutics' Debt to Equity rose 37.01% to $0.04 in Q2 2023 from the same period last year, while for Jun 2023 it was $0.04, marking a year-over-year increase of 37.01%. This contributed to the annual value of $0.04 for FY2022, which is 43.63% up from last year.
  • Per C4 Therapeutics' latest filing, its Debt to Equity stood at $0.04 for Q2 2023, which was up 6.41% from $0.04 recorded in Q1 2023.
  • In the past 5 years, C4 Therapeutics' Debt to Equity registered a high of $0.04 during Q2 2023, and its lowest value of -$0.06 during Q3 2020.
  • For the 3-year period, C4 Therapeutics' Debt to Equity averaged around $0.03, with its median value being $0.03 (2022).
  • Within the past 5 years, the most significant YoY rise in C4 Therapeutics' Debt to Equity was 141.91% (2021), while the steepest drop was 22.80% (2021).
  • Quarterly analysis of 4 years shows C4 Therapeutics' Debt to Equity stood at $0.04 in 2020, then declined by 22.80% to $0.03 in 2021, then surged by 43.63% to $0.04 in 2022, then surged by 37.01% to $0.04 in 2023.
  • Its Debt to Equity stands at $0.04 for Q2 2023, versus $0.04 for Q1 2023 and $0.04 for Q4 2022.